Overview
- The peer-reviewed study, published Oct. 20–21, 2026, tested a whole-genome sequencing (WGS) liquid biopsy approach in 42 patients with stage IA non–small-cell lung cancer to build individualized mutational signatures.
- Researchers compared serial plasma WGS to imaging and found the blood test predicted recurrence with reported 0.75 sensitivity, 0.83 specificity, and a median 16.7-month lead time over clinical or imaging detection.
- The method pairs patient-specific tumor fingerprints with an AI pattern-recognition algorithm to pull tiny traces of circulating tumor DNA (ctDNA) from blood and distinguish true recurrence from a second primary tumor.
- Clinically, earlier detection of minimal residual disease could let doctors start targeted therapy sooner for high-risk patients and reduce unnecessary treatment for low-risk patients, changing follow-up and treatment decisions.
- Findings are promising but preliminary because the study used a small single-center cohort, so larger multicenter and prospective trials are needed to confirm accuracy, cost-effectiveness, and guideline adoption.